Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

266.87
-4.4900-1.65%
Volume:1.11M
Turnover:296.71M
Market Cap:471.66B
PE:75.39
High:271.61
Open:270.98
Low:266.10
Close:271.36
52wk High:274.94
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.63
T/O Rate:0.06%
Dividend:6.83
Dividend Rate:2.56%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-79.47
PE(LYR):113.08

Loading ...

AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Aug 27

Gubra Earns USD 50 Million Milestone as AbbVie Starts Phase 2 Trial of Obesity Drug ABBV-295

Reuters
·
Aug 26

Uni-Bio Science H1 Revenue Falls 12% on Pricing Changes

Reuters
·
Aug 26

China's Shandong Xinhua Profit Drops on Domestic, International Competition

Reuters
·
Aug 25

China's Innovent Biologics H1 Revenue, Profit Rise on Strong Product Sales

Reuters
·
Aug 25

Austar Lifesciences H1 Profit Drops on Higher R&D Spending

Reuters
·
Aug 25

WuXi Biologics H1 Net Profit up on Margin Expansion

Reuters
·
Aug 25

Stick with Value Stocks Until Everyone Starts Talking About Them - and as of Now They're Still Under the Radar, This Wall Street Firm Says

Dow Jones
·
Aug 25

Molecular Partners H1 Net Loss Narrows on Lower R&D Expenses

Reuters
·
Aug 25

Oruka Therapeutics Names Todd Edwards Chief Commercial Officer

Reuters
·
Aug 25

Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?

Simply Wall St.
·
Aug 25

ANI Pharma Appoints Henry Gosebruch to Board of Directors

Reuters
·
Aug 24

Johnson & Johnson, AbbVie, Chevron, Energy Transfer, Home Depot Shaken

TIPRANKS
·
Aug 22

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 22

AbbVie Expands Aesthetics Pipeline With New Phase 2 Forehead Lines Study

TIPRANKS
·
Aug 22

AbbVie Targets Pediatric Alopecia With New Phase 3 Trial: What Investors Should Watch

TIPRANKS
·
Aug 22

AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now

TIPRANKS
·
Aug 22

AbbVie Targets Next-Gen BOTOX Combo With New Glabellar Lines Study

TIPRANKS
·
Aug 21

AbbVie Price Target Raised to $303.00/Share from $298.00 by Piper Sandler

Dow Jones
·
Aug 21

AbbVie price target raised to $303 from $298 at Piper Sandler

TIPRANKS
·
Aug 20